Thank you for your inquiry.
We will contact you within a few business days.
(Business Unit Performance Materials, Sales Support Team)
Gedung AIA Central, Level 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesia
+62 21 2988 8557
Success! Your inquiry has been submitted to our Sales team.
Something went wrong! Please try after some time.
We have found 19 items.
| Requestor's contact details | |
| Full name | |
| Company | |
| Position | |
| Telephone number | |
| Work email address | |
| Shipping address | |
Thank you. Your request has been sent.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Urapidil Base is a white crystalline powder. When dissolved, it forms a clear, colorless solution that is free of particles.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Refarmed Chemicals presents Ciprofibrate, a crucial pharmaceutical material developed for clinical efficacy in managing lipid disorders. Developed with the utmost precision, Ciprofibrate is a fibrate-class drug specially formulated as a therapeutic agent to regulate high levels of cholesterol and triglycerides, factors leading to cardiovascular diseases. Our product is synthesized with rigorous compliance to quality standards, evidenced by its Good Manufacturing Practice (GMP) certification. The drug appears as a white or slightly yellow-white crystalline powder, indicative of its purity. Highly soluble in anhydrous ethanol and toluene yet practically insoluble in water, Ciprofibrate facilitates flexibility in pharmaceutical formulation, allowing for both tablet and capsule dosage forms in strengths of 100mg and 200mg. Targeting primary hypercholesterolemia (type IIa or IIb), mixed dyslipidemia, and as preventive treatment against cardiovascular events in high cholesterol patients, Ciprofibrate's composition facilitates the acceleration of cholesterol and triglyceride breakdown and removal from the body. Recommended for bi-daily intake alongside meals, the treatment's efficacy is augmented by adherence to healthy lifestyle choices, including a balanced diet and regular exercise. Safety parameters dictate careful administration especially to those with a history of gallbladder disease, and periodic liver function evaluations are advised. Contraindications include severe renal or hepatic conditions, pregnancy, breastfeeding, or known hypersensitivity to fibrates. Consultation with healthcare professionals is critical when concomitant medications are involved, particularly statins, anticoagulants, and antibiotics. Storage requirements for Ciprofibrate are straightforward — room temperature conditions away from light and moisture ensure stability. As a product from the storied catalogue of Refarmed Chemicals, now part of the DKSH Group, Ciprofibrate is accompanied by dependable documentation for Detailed and Master Files, affirming its reputable standard in pharmaceutical resources.
Products still subject to third-party patent protection might be available solely for R&D purposes.